Risk of adverse events of psoriasis treatment with biologic agents and new small molecules—BIOBADADERM Registry
J Eur Acad Dermatol Venereol 2025;39:1643–55 Doi: 10. 1111/ jdv. 20831
This study by Olivares-Guerrero et al. provides comparative safety data from a clinical practice point of view, potentially contributing to facilitate the drug selection process for clinicians. New biologic treatments have a superior safety profile in real-world practice compared to adalimumab and its biosimilars. Olivares-Guerrero et al. used data from the BIOBADADERM registry of AEs to analyse the long-term safety profile of systemic treatments, including biological agents as well as new small oral molecules approved for the treatment of moderate-to-severe PsO, using adalimumab and its biosimilars as comparators.
Establishing effective long-term treatment strategies is crucial for management of PsO, since this is a chronic disease that frequently requires long-term therapy. The author’s findings provide a useful tool for clinicians to support decision-making and individualizing treatment strategies in patients with moderate-to-severe PsO.
Keywords:
